Related Experiment Video
Updated: Mar 24, 2026

Direct Drug Delivery to Kidney via the Renal Artery
Published on: April 17, 2021
Orphan devices: yesterday is history; tomorrow is mystery: towards a European orphan device directive?
1University Hospitals Leuven, Leuven, Belgium. dooms@evonet.be.
Background:
Regulatory and economic frameworks stimulated the research and development of orphan drugs, but very little has been done for devices necessary for the in-vivo diagnosis, prevention and treatment of life-threatening conditions with a low prevalence/incidence.
Discussion:
A general public consultation in Europe has shown a positive attitude towards an "orphan device" directive. The United States of America have a Humanitarian Use Device exemption, but Europe is still waiting for such a stimulating framework. Post-marketing surveillance ("materio-vigilance") will be necessary for follow-up, patient-reported outcome measures (quality of life versus survival) needed and off-label use data available for patient-safety reasons. The marketing period for devices is shorter than for medicinal products. Incentives are necessary to stimulate research and development of such "orphan devices" especially when surgical intervention is the only option.
Related Concept Videos
Prescription, Nonprescription and Orphan Drugs
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
Drug Regulation
FDA Approved Drugs: Changes to Approved Drugs
Clinically Relevant Drug Product Specifications: Methods of Establishment
Drug Products: Biologics, Biosimilars and Interchangeables
Drug Nomenclature

